Myeloperoxidase induces the priming of platelets

H Kolarova1, A Klinke2, S Kremserova1

  • 1Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic; Department of Animal Physiology, Faculty of Science, Masaryk University, Brno, Czech Republic.

Insights

Myeloperoxidase (MPO) binds to and activates platelets, impairing nitric oxide production and promoting inflammatory cell interactions. This platelet priming may contribute to chronic vascular inflammation.

Area of Science:

  • Cardiovascular Research
  • Immunology
  • Hematology

Background:

  • Myeloperoxidase (MPO) released during vascular inflammation is implicated in disease pathogenesis.
  • The specific role of MPO in platelet function and vascular inflammatory diseases remains unclear.

Purpose of the Study:

  • To investigate the interaction between MPO and platelets.
  • To determine the effects of MPO on platelet function and viability.

Main Methods:

  • Dose-dependent binding assays of MPO to human and mouse platelets.
  • Localization studies of MPO within platelets.
  • Assessment of MPO's effects on nitric oxide (NO) production, platelet viability, surface receptor expression (P-selectin, PECAM-1), reactive oxygen species (ROS) generation, and interaction with polymorphonuclear leukocytes (PMNs).

Main Results:

  • MPO dose-dependently binds to and localizes within platelets, preserving its enzymatic activity.
  • MPO binding decreases platelet NO production and impairs platelet viability during long-term storage.
  • MPO induces partial platelet activation, increasing P-selectin and PECAM-1 expression and ROS generation, but not aggregation or granule release. MPO-treated platelets show increased interaction with PMNs.

Conclusions:

  • MPO interacts with and primes platelets, rather than causing full activation.
  • This MPO-induced platelet priming may contribute to the development of chronic vascular inflammatory conditions.

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...